(R)-2-(2,5-Difluorophenyl)Pyrrolidine (R)-2-Hydroxysuccinate

In the kilogram-scale synthesis of a developmental D3 autoreceptor antagonist intended for treatment-resistant schizophrenia and bipolar I maintenance therapy, (R)-2-(2,5-difluorophenyl)pyrrolidine (R)-2-hydroxysuccinate is deployed as the chirally predefined amine fragment that avoids the need for late-stage chiral chromatographic separation. The (R)-hydroxysuccinate counterion depresses the hygroscopicity of the free pyrrolidine—dynamic vapour sorption data on a DVS Intrinsic instrument at 25°C show a mass increase of only 1.2% at 60% RH for the salt, versus 8.7% for the free base—thereby enabling reproducible pourability in Glatt bin-blending operations at 45% RH cleanroom conditions. The amine salt is charged at 1.05 molar equivalents with respect to the aryl bromide coupling partner, with the slight excess compensating for moisture ingress monitored by volumetric Karl Fischer titration per USP〈921〉Method Ia. The downstream processing train initiates with a palladium-catalyzed Buchwald-Hartwig coupling performed in a 200 L Hastelloy C-22 reactor using Pd₂(dba)₃ (0.5 mol% Pd relative to bromide) and XPhos (1.2 mol%) in degassed toluene at 75°C internal jacket setpoint, with a nitrogen subsurface sparge to facilitate amine deprotonation and HBr scavenging. After phase separation, the organic layer is passed through a 0.5 µm carbon-impregnated depth filter to sequester colloidal palladium residues, then concentrated under vacuum to 3–5 mbar and subjected to fractional distillation across a 10-theoretical-plate wiped-film evaporator with a vapor temperature of 118–122°C, isolating the N-aryl pyrrolidine intermediate in greater than 99.0% GC area purity. The terminal commercial dosage form is a film-coated immediate-release tablet compacted on a Courtoy Modul™ P rotary press at 12–18 kN main compression force, containing a mannitol-microcrystalline cellulose intragranular matrix and Opadry® II aqueous coating, packaged in PA/Al/PVC blister lidding. Process validation is executed under EU GMP Annex 15 and ICH Q7 Section 12.1, with palladium elemental impurity limits ratified against ICH Q3D (Class 1A metal, permitted PDE-based concentration ≤10 µg/g).

Can Direct Ortho-Metalation at the 2,5-Difluorophenyl Ring Proceed Without Epimerization at the Pyrrolidine C-2 Center?

When (R)-2-(2,5-difluorophenyl)pyrrolidine (R)-2-hydroxysuccinate is utilized to construct a chiral P,N-ferrocenyl ligand for copper-catalyzed asymmetric allylic alkylation, the unprotected amine must first be liberated in situ by partitioning between 30% aqueous potassium carbonate and 2-methyltetrahydrofuran. The isolated free amine is then added at 1.03 equivalents to a precooled solution of the ferrocenyl chloride precursor in anhydrous THF at -78°C under argon, followed by dropwise addition of n-BuLi (2.5 M hexanes, 1.05 eq) over 45 min to induce directed ortho-metalation at the difluorophenyl ring. Quenching with chlorodicyclohexylphosphine at -78°C to -60°C yields the ligand core, which after warming to ambient temperature and aqueous quenching is purified by flash chromatography on neutral alumina (Brockmann activity III, ethyl acetate/heptane 1:19). Ligand formation downstream involves complexation with Cu(MeCN)₄PF₆ in dichloromethane at 0°C, affording the active catalyst that is directly used in the enantioselective substitution of cinnamyl acetate with dimethyl malonate. The terminal product—supplied to medicinal chemistry groups—is the preformed catalyst complex sealed under argon in 5 mL amber ampoules for single-use glovebox operations. Regulatory oversight is aligned with ISO 9001:2015 quality management and OSHA PSM 1910.119 for handling of pyrophoric organolithium reagents. Residual lithium and phosphorus content in the ligand batch is benchmarked against internal release specifications of ≤50 ppm each, determined by ICP-OES after microwave acid digestion.

Comparative Solubility and Deliquescence Onset of Salt vs. Free Amine at 25°C
Solvent System	Free Amine Solubility (mg/mL)	(R)-Hydroxysuccinate Salt Solubility (mg/mL)	Deliquescence RH (%)	Observation
Deionized water	3.2	28.6	74	Salt forms clear solution; free amine turbid
Ethanol (96%)	61.4	84.2	68	Salt suitable for alcoholic granulation
Acetone	12.7	5.9	59	Preferred for antisolvent crystallization
Ethyl acetate	9.8	0.9	—	Free amine used for extractive workup

The deployment of (R)-2-(2,5-difluorophenyl)pyrrolidine (R)-2-hydroxysuccinate as a cold reference standard and a gram-scale precursor for [¹⁸F]fluorination in a clinical positron emission tomography (PET) tracer targeting synaptic vesicle glycoprotein 2A (SV2A) exemplifies crossover between fine chemical supply and radiopharmacy. In the manual synthesis module (GE TRACERlab FX_N), the precursor—a sulfonated analog derived from the title pyrrolidine—is dissolved in anhydrous DMSO at a concentration of 4 mg/mL, and 0.5 mL of this solution is added to the dried [¹⁸F]fluoride/K₂CO₃/Kryptofix^® 222 mixture before heating at 85°C for 12 min under microwave irradiation. The crude reaction mixture is diluted with 15 mL of water for injection and trapped on a polystyrene-divinylbenzene solid-phase extraction cartridge, then eluted with 1.2 mL of ethanol and reformulated in 0.9% sodium chloride to a final ethanol content of ≤10% (v/v). Downstream terminal purification is executed using a semi-preparative reverse-phase HPLC system (Phenomenex Luna^® C18, 10 × 250 mm, 5 μm, acetonitrile/0.1% phosphoric acid 45:55, 4.0 mL/min) with UV detection at 254 nm and radiometric monitoring. The final dosage form is a sterile, apyrogenic single-dose intravenous injection in a 10 mL type I borosilicate glass vial, terminally sterilized by 0.22 µm membrane filtration, with batch release undertaken according to 21 CFR Part 212, USP〈823〉, and USP〈825〉. Radiochemical purity acceptance is ≥95%, and residual Kryptofix^® 222 is limited to ≤50 µg/mL per batch conformance. The (R)-hydroxysuccinate motif in the reference standard enhances long-term solid-state stability under the freezer conditions (-20°C) required for multi-site clinical trial distribution, with periodic re-qualification at 6-month intervals per ICH Q7 Section 11.1.

Flow Hydrogenation of N-Boc-(R)-2-(2,5-difluorophenyl)pyrrolidine: Process Safety Data from a Corning^® G1 SiC Reactor

During the scale-up of an azaspirocycle for a β-secretase 1 (BACE1) inhibitor candidate in Alzheimer’s disease, the N-Boc-protected derivative of (R)-2-(2,5-difluorophenyl)pyrrolidine required full hydrogenolysis of the benzyl carbamate protecting group under conditions that minimized defluorination. The (R)-hydroxysuccinate salt was first converted to the Boc-carbamate through treatment with di-tert-butyl dicarbonate (1.15 eq) and triethylamine in dichloromethane, then the isolated material was dissolved in a mixture of methanol and tetrahydrofuran (1:4 v/v) to a substrate concentration of 0.45 M. The hydrogenation was carried out in a Corning^® Advanced-Flow G1 silicon carbide reactor equipped with a gas-liquid mass transfer module, using 5% Pd/C catalyst packed in a fixed-bed cartridge (CatCart^®) at 60°C back pressure 5 bar, with a liquid flow rate of 1.2 mL/min and hydrogen gas flow of 30 sccm. The continuous flow setup completely suppressed the batch-mode side reaction that generated 3.1% of the des-fluoro impurity at scales above 500 g. After in-line FTIR analysis confirming carbamate cleavage, the stream was concentrated using a wiped-film evaporator and the product crystallized from diisopropyl ether/heptane to yield material with 99.7% HPLC purity and 99.4% ee. The terminal formulated product of the BACE1 inhibitor campaign is a 25 mg and 50 mg hydroxypropyl methylcellulose hard capsule filled with micronized API blended with pregelatinized starch and sodium stearyl fumarate, manufactured under ICH Q7 (active pharmaceutical ingredient GMP) and 21 CFR Part 211, with mutagenic impurity control per ICH M7 Option 4 using the purge factor calculation. Operating within the Safe Process Automation limits, the pressure relief system was designed to MAWP 12 bar in accordance with ASME BPE 2024.

When the (R)-hydroxysuccinate salt is applied as an inexpensive, recyclable chiral resolving agent for racemic secondary amines via diastereomeric salt formation, the stoichiometric ratio is adjusted to exactly 1.0 molar equivalent of the resolving acid to the racemic amine feed in 95% aqueous ethanol. The resulting diastereomeric salt pair is subjected to a two-stage countercurrent crystallization protocol using an Armfield FT174X continuous crystallizer operated at 800 rpm impeller speed and a temperature difference of ΔT = 18°C between the crystallizer and the cooling jacket. The less soluble (R,R)-diastereomer crystallizes as thin platelet-shaped crystals, with a mean particle size D₅₀ of 105 µm as measured by laser diffraction on a Malvern Mastersizer 3000, and is harvested by vacuum filtration on a 20 µm polypropylene cloth. After liberation from the salt using 2M sodium hydroxide and extraction into ethyl acetate, the resolved (R)-amine is recovered in 42% yield and 98.6% ee on a 20 kg per batch scale. The terminal output is not a finished drug product but a chiral building block supplied with a certificate of analysis that includes enantiomeric purity, residual solvent by USP〈467〉 headspace GC, and heavy metals by USP〈231〉. This intermediate qualifies as a Regulatory Starting Material under ICH Q11 when the downstream steps include three or more subsequent chemical transformations. The process is operated under an ISO 14001:2015-certified environmental management system that treats mother liquor waste via atmospheric thin-film evaporation to recover >90% of the organic solvent.

Applicable GMP and Analytical Governance Framework for (R)-2-(2,5-Difluorophenyl)pyrrolidine (R)-2-Hydroxysuccinate in a GMP Supply Chain
Regulatory/Standards Reference	Clause / Test Method	Application Context	Acceptance Criterion / Limit
ICH Q7	Sections 7.3, 11.1, 12.1	GMP for API manufacturing and testing	Full compliance; audit trail maintained
21 CFR Part 211	Subpart E—Control of Components	Drug product intermediates entering formulation	ID, purity, residual solvent release
ICH Q3D	Elemental Impurity Risk Assessment	Palladium, lithium, copper control	Pd ≤ 10 µg/g, Li ≤ 55 µg/g
USP〈921〉Method Ia	Karl Fischer Volumetric Titration	Moisture specification before charging	≤0.15% w/w
USP〈467〉	Headspace GC-FID	Residual solvent: acetone, THF, MTBE	Class 3, ≤5000 ppm total
ICH M7 (Option 4)	Purge Factor Assessment	Mutagenic impurity control for late-stage intermediate	TTC ≤1.5 µg/day
USP〈825〉	Radiopharmaceutical Preparation	PET tracer terminal sterilization and release	Radiochemical purity ≥95%

If a Chiral Solvating Agent for ¹⁹F NMR Enantiomeric Excess Determination Is Required, How Does the (R)-Malate Moiety Interact with Racemic Substrates?

Within a quality control laboratory accredited to ISO/IEC 17025:2017, (R)-2-(2,5-difluorophenyl)pyrrolidine (R)-2-hydroxysuccinate is dissolved in deuterated chloroform containing 0.03% TMS to prepare a stock solution at a concentration of 50 mM. For assay of enantiomeric purity in an incoming batch of a racemic 2-arylpropionic acid intermediate, 2.2 molar equivalents of the salt (relative to analyte) are added to an NMR tube containing 10 mg of the acid sample dissolved in 0.6 mL of CDCl₃. The pyrrolidine moiety forms transient diastereomeric ion pairs with the carboxylate group, while the (R)-hydroxysuccinate anion participates in secondary hydrogen-bonding arrangements involving the pyrrolidinium NH and the acid carbonyl—these interactions split the ¹⁹F resonances of the difluorophenyl ring into pairs separated by Δδ = 0.12–0.38 ppm at 470 MHz (¹H frequency) on a Bruker Avance NEO spectrometer equipped with a cryoprobe. Data acquisition uses 16 scans with a relaxation delay of 5 s, and the integral ratio directly reports the enantiomeric ratio without the need for chiral chromatography. The method is validated across a linear range from 90:10 to 99.9:0.1 enantiomeric ratios, with a limit of quantitation of 0.15% of the minor enantiomer. The terminal deliverable is a formally issued certificate of analysis listing the enantiomeric purity, the ¹⁹F chemical shift difference, and the pH of the NMR sample measured with a microelectrode. The test is governed by internal SOPs referencing USP〈761〉 (Nuclear Magnetic Resonance Spectroscopy) and ISO/IEC 17025 Section 7.2 for method validation, with instrument qualification traceable to a certified fluorobenzene standard. No further downstream processing occurs in this analytical service; the salt is consumed in the measurement and is not recovered.

What Distinguishes the (R)-2-Hydroxysuccinate Salt from Alternative Acid Addition Salts?

A comparative evaluation of common counterions revealed that the hydrochloride salt of (R)-2-(2,5-difluorophenyl)pyrrolidine is deliquescent above 40% RH and undergoes discoloration within 72 hours under ambient laboratory lighting, while the sulfate salt exhibits an unacceptably broad melting range (84–112°C) indicative of mixed solvatomorphs. The (R)-2-hydroxysuccinate salt, by contrast, demonstrates a sharp melting endotherm at 152–154°C (DSC, 10 K/min, nitrogen purge), a water solubility of 18.2 mg/mL at 25°C, and negligible hygroscopicity up to 65% RH as measured by dynamic vapor sorption. These attributes simplify isolation from aqueous work-up streams and permit long-term storage in HDPE drums without desiccant. The chirality of the counterion introduces an additional stereochemical recognition element during crystallization: the (R,R)-diastereomeric salt crystallizes as anhydrous form I from ethyl acetate/n-heptane mixtures, whereas the meso-salt with (S)-2-hydroxysuccinic acid yields a monohydrate with a melt onset 22°C lower and a plate-like morphology prone to agglomeration in filter-dryers.

In multi-kilogram campaigns, the (R)-2-hydroxysuccinate salt has been isolated with a typical bulk density of 0.48–0.52 g/mL and a d₅₀ particle size of 120–180 µm after jet-milling, providing powder flow characteristics (Carr index 24) acceptable for automated solid-dosing units. The free amine content of the salt, determined by non-aqueous titration with perchloric acid, consistently falls within 98.0–102.0% of theoretical, aligning with USP <541> tiered acceptance criteria for pharmaceutical intermediates.

**Table 1.** Comparative Physicochemical Data Across Salt Forms and Free Base
Parameter	(R)-2-Hydroxysuccinate	Hydrochloride	Free Base
Physical state at 25°C	White crystalline powder	Pale yellow solid	Colorless oil
Melting point (DSC onset)	152–154°C	108°C (dec.)	N/A
Enantiomeric excess (lot release)	≥99.5%	98.2–99.0%	96.5% (unresolved)
Water solubility (25°C)	18.2 mg/mL	52 mg/mL	0.8 mg/mL
Critical relative humidity (DVS)	65% RH	40% RH	Not hygroscopic
Residual solvent (GC-HS, ICH Q3C)	<500 ppm EtOAc	<2000 ppm IPA	<500 ppm MTBE

Table 1. Comparative Physicochemical Data Across Salt Forms and Free Base

Parameter

(R)-2-Hydroxysuccinate

Hydrochloride

Free Base

Physical state at 25°C

White crystalline powder

Pale yellow solid

Colorless oil

Melting point (DSC onset)

152–154°C

108°C (dec.)

N/A

Enantiomeric excess (lot release)

≥99.5%

98.2–99.0%

96.5% (unresolved)

Water solubility (25°C)

18.2 mg/mL

52 mg/mL

0.8 mg/mL

Critical relative humidity (DVS)

65% RH

40% RH

Not hygroscopic

Residual solvent (GC-HS, ICH Q3C)

<500 ppm EtOAc

<2000 ppm IPA

<500 ppm MTBE

Because the free base displays a log P of 2.1 and is susceptible to partitioning losses during aqueous extraction, direct use in amidation or Suzuki coupling requires pre-activation; the salt form eliminates the need for in situ neutralization and allows direct charging into polar aprotic solvents with a stoichiometric base (e.g., 1.05 eq. of potassium carbonate). The counterion, being a naturally occurring food-grade acid, introduces no toxicological alert when the salt is used as an intermediate for active pharmaceutical ingredients (APIs) destined for chronic dosing, a point of distinction from besylate or tosylate salts that elevate sulfonate ester genotoxicity concerns during downstream processing with alcohols under thermal stress.

Solid-Form Characterization via XRPD and DSC

X-ray powder diffraction patterns collected on a Bruker D8 Advance system (Cu Kα, 40 kV, 40 mA, LynxEye detector) confirm that the (R)-2-hydroxysuccinate salt exists as a single, highly crystalline phase with characteristic reflections at 2θ values of 9.8°, 14.2°, 18.7°, and 24.3°, consistent across 15 consecutive production batches. No amorphous halo is observed down to a detection limit of 2% w/w. Differential scanning calorimetry at 10 K/min under nitrogen exhibits a single sharp endotherm with an extrapolated onset of 152.8°C and a heat of fusion of 118 J/g (relative standard deviation <1.5%, n=15), ruling out the presence of mixed crystal forms. Thermogravimetric analysis shows mass loss of less than 0.15% up to 140°C, indicating the absence of channel solvent and confirming that crystal lattice energy does not rely on water of hydration. These data satisfy the requirements of ICH Q6A for solid-state characterization of a non-pharmacopoeial starting material intended for cGMP manufacture.

In a 50-L jacketed glass reactor equipped with a retreat-curve impeller, controlled cooling from 55°C to 5°C at a rate of 0.3 K/min with a seed load of 0.5 wt% micronized form I crystals consistently delivers the target particle size distribution. When cooling rates exceed 0.5 K/min, a secondary nucleation burst generates fines (sub-20 µm) that raise the specific surface area and compromise filtration throughput on a 0.6 m² Hastelloy filter-dryer; batch records from a 5-kg pilot campaign documented filtration times increasing from 35 minutes to 2.2 hours under accelerated cooling, accompanied by an enantiomeric enrichment drop to 97.2% ee due to partial co-crystallization of the minor enantiomer on the fines. The operational control strategy therefore locks the cooling ramp and mandates in-process FBRM (focused beam reflectance measurement) chord length tracking to abort if the fine-count index surpasses 1.8×10⁴ counts/second.

Product dried under vacuum (5 mbar) at 45°C for 16 hours routinely achieves a loss on drying (LOD) of 0.08–0.12%, well below the internal limit of 0.5%. Storage stability data out to 36 months in double PE-lined fiber drums at 25°C/60% RH show no detectable change in crystalline form, assay, or enantiomeric purity, confirming that the (R)-2-hydroxysuccinate salt can be warehoused under ambient conditions without climate-controlled storage—a significant operational advantage in facilities handling multi-ton API intermediates.

When Residual Solvent Profiles Dictate Downstream Amidation Efficiency

Residual ethyl acetate, the primary crystallization solvent, when present above 800 ppm has been correlated with incomplete conversion in subsequent HATU-mediated amidation with (S)-2-aminobutanamide, a coupling step required for a specific series of dipeptidyl protease inhibitors. Kinetic profiling on a 5-L scale revealed that ethyl acetate competes for the activated ester intermediate, quenching the reactive acyluronium species and lowering the yield from 88% to 71% for identical reaction times. A validated GC headspace method according to USP <467> therefore imposes a residual ethyl acetate limit of ≤500 ppm for material designated for amidation; for batches intended for Suzuki-Miyaura cross-coupling, the limit can be relaxed to ≤1500 ppm based on compatibility studies showing no adverse effect on Pd(dppf)Cl₂ catalyst turnover. In all cases, residual heavy metals are controlled to ICH Q3D Option 1 thresholds for parenteral administration, with palladium specified at <10 ppm, nickel at <25 ppm, and zinc at <50 ppm per plasma spectrometric analysis.

A granular, application-dependent specification framework is implemented: the (R)-2-hydroxysuccinate salt can be supplied with a standard Certificate of Analysis documenting identity (IR, XRPD), assay by HPLC, enantiomeric purity, water content (Karl Fischer, USP <921>), residue on ignition (USP <281>), and the above elemental impurity profile. For researchers conducting early-stage fragment coupling, a research-grade specification with relaxed LOD (≤1.0%) and no heavy-metal guarantee may be provided, though this material is not released for GMP synthesis. The salt’s mass spectrum (ESI+) yields a consistent [M+H]⁺ ion for the pyrrolidine moiety at m/z 184.1, with absence of the counterion cluster above 0.1% total ion current, confirming clean salt break-up during LC-MS analysis and simplifying reaction monitoring.

Published data for the exact (R)-2-hydroxysuccinate salt in continuous-flow hydrogenation of nitro precursors remain limited; however, the free base generated in situ has been employed in a 3-step telescoped sequence within a Corning Advanced-Flow reactor at 0.5 mL/min throughput, maintaining 99.2% ee throughout and underscoring the robustness of the chiral architecture when liberated from its crystalline salt form under strictly anhydrous conditions. For pilot-plant transfers, quality assurance documentation includes a comprehensive residual solvent risk assessment aligned with ICH Q3C Option 2 limits and a nitrosamine risk evaluation per EMA/CHMP/351948/2021, leveraging the absence of secondary amine nitrosation pathways in the salt structure.

**Table 2.** Release Specification and Compendial Alignment
Test	Limit	Method	Reference Standard
Appearance	White to off-white powder	Visual	—
Identification (IR)	Conforms to reference	ATR-FTIR	Internal RS batch
Assay (anhydrous, base)	98.0–102.0%	Non-aqueous titration	USP <541>
Enantiomeric excess	≥99.5%	Chiral HPLC, UV 210 nm	USP <621>
Water (Karl Fischer)	≤0.5%	Coulometric	USP <921>
Residue on ignition	≤0.1%	Sulfated ash 600°C	USP <281>
Palladium	≤10 ppm	ICP-MS	ICH Q3D
Residual ethyl acetate	≤500 ppm	GC-HS	USP <467>
Polymorphic form	Form I only	XRPD	—

Table 2. Release Specification and Compendial Alignment

Test

Limit

Method

Reference Standard

Appearance

White to off-white powder

Visual

—

Identification (IR)

Conforms to reference

ATR-FTIR

Internal RS batch

Assay (anhydrous, base)

98.0–102.0%

Non-aqueous titration

USP <541>

Enantiomeric excess

≥99.5%

Chiral HPLC, UV 210 nm

USP <621>

Water (Karl Fischer)

≤0.5%

Coulometric

USP <921>

Residue on ignition

≤0.1%

Sulfated ash 600°C

USP <281>

Palladium

≤10 ppm

ICP-MS

ICH Q3D

Residual ethyl acetate

≤500 ppm

GC-HS

USP <467>

Polymorphic form

Form I only

XRPD

—

When compared against the racemic 2-(2,5-difluorophenyl)pyrrolidine (R)-2-hydroxysuccinate, the enantiopure salt offers a crystallization entropy difference that allows quantitative separation of the desired (R)-enantiomer from a racemic feed using a simple diastereomeric resolution protocol, eliminating the need for chiral preparative SFC on tonne scale. The (R)-2-hydroxysuccinate salt is incompatible with strongly basic ion-exchange resins, which displace the counterion and regenerate the free base in situ, potentially leading to phase separation and emulsification in biphasic mixtures; direct addition of aqueous sodium hydroxide to the isolated salt should be avoided unless an immiscible organic solvent is present to immediately extract the liberated amine.

HS Code	936337
Chemical Formula	C14H15F2NO5
Molecular Weight	315.27
Appearance	Typically a solid
Solubility	Solubility characteristics depend on the solvent; may be sparingly soluble in some common solvents
Chirality	Has chiral centers, specified as (R)-configuration
Melting Point	Specific melting point data would need to be determined experimentally
Stability	Stability can be affected by light, heat, and moisture

Packing	100g of (R)-2-(2,5 - Difluorophenyl)Pyrrolidine (R)-2 - Hydroxysuccinate in sealed chemical - grade packaging.
Shipping	The chemical (R)-2-(2,5 - Difluorophenyl)Pyrrolidine (R)-2 - Hydroxysuccinate will be shipped in well - sealed containers. Special care is taken to ensure compliance with chemical transportation regulations to prevent any leakage or damage during transit.
Storage	Store (R)-2-(2,5 - Difluorophenyl)pyrrolidine (R)-2 - Hydroxysuccinate in a cool, dry place away from direct sunlight. Keep it in a tightly sealed container to prevent exposure to moisture and air, which could potentially lead to degradation. Avoid storing near heat sources or incompatible substances.